Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
- PMID: 30713046
- PMCID: PMC6401262
- DOI: 10.1016/j.mayocp.2018.08.041
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
Abstract
Objective: To determine the incidence of immunoglobulin light chain amyloidosis (AL amyloidosis) in a strictly defined geographic area from 1990 through 2015.
Patients and methods: We searched a computerized database for the records of all Olmsted County, Minnesota, residents with a diagnosis of AL amyloidosis from January 1, 1990, through December 31, 2015. In addition, records of all residents with a mention of amyloidosis were obtained from the Rochester Epidemiology Project, which contains the medical records of Mayo Clinic and Olmsted Medical Group. The diagnosis of AL amyloidosis was determined by mass spectrometry, immunohistochemical analysis, or positive Congo red staining.
Results: Thirty-five patients were identified as having AL amyloidosis. The median age at diagnosis was 76 years (range, 38-90 years), with men accounting for 54%. The incidence rate of AL amyloidosis from 1990 through 2015 adjusted for age and sex was 1.2 per 100,000 person-years (95% CI, 0.8-1.6 per 100,000 person-years). Rates were similar across the decades 1990-1999, 2000-2009, and 2010-2015 at 1.1, 0.9, and 1.6 per 100,000 person-years, respectively, with no suggestion of an increasing rate during the 26 years. There was a trend toward an increasing incidence over time from 1950 through 2015 in Olmsted County, but it was not significant (P=.15). Applying the rate of 1.2 per 100,000 person-years to the US population of 321 million in 2015, one would expect 3852 new cases of AL amyloidosis in the United States each year.
Conclusion: The incidence of AL amyloidosis in Olmsted County has not changed significantly in the past 66 years.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest Disclosure: Dr. Dispenzieri has research support from Prothena, Jannsen, Alnylam, Celgene, Takeda, Pfizer and GSK. Dr. Kumar has research grants for clinical trials to the institution: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech and Amgen. Consulting with no personal payments: Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune,Genentech, Oncopeptides and Amgen. IRC chair: Oncopeptides. Honorarium: Dr. Reddys Lab. The other authors have nothing to disclose.
Figures
Comment in
-
Robert A. Kyle, MD: Lessons From a Legend.Mayo Clin Proc. 2019 Mar;94(3):375-376. doi: 10.1016/j.mayocp.2019.01.030. Mayo Clin Proc. 2019. PMID: 30832784 No abstract available.
-
New Insights Into a Multifaceted Disease.Mayo Clin Proc. 2019 Mar;94(3):388-390. doi: 10.1016/j.mayocp.2019.01.029. Mayo Clin Proc. 2019. PMID: 30832787 No abstract available.
Similar articles
-
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.Blood. 1992 Apr 1;79(7):1817-22. Blood. 1992. PMID: 1558973
-
Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.J Clin Oncol. 1994 Aug;12(8):1577-83. doi: 10.1200/JCO.1994.12.8.1577. J Clin Oncol. 1994. PMID: 8040670
-
Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County.Clin J Am Soc Nephrol. 2020 Jan 7;15(1):69-79. doi: 10.2215/CJN.05900519. Epub 2019 Dec 2. Clin J Am Soc Nephrol. 2020. PMID: 31791998 Free PMC article.
-
A population-based study of the incidence of delusional infestation in Olmsted County, Minnesota, 1976-2010.Br J Dermatol. 2014 May;170(5):1130-5. doi: 10.1111/bjd.12848. Br J Dermatol. 2014. PMID: 24472115 Free PMC article. Review.
-
Global epidemiology of amyloid light-chain amyloidosis.Orphanet J Rare Dis. 2022 Jul 19;17(1):278. doi: 10.1186/s13023-022-02414-6. Orphanet J Rare Dis. 2022. PMID: 35854312 Free PMC article.
Cited by
-
Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.Clin Hematol Int. 2022 Sep;4(3):117-120. doi: 10.1007/s44228-022-00014-6. Epub 2022 Jul 29. Clin Hematol Int. 2022. PMID: 36131130 Free PMC article. No abstract available.
-
Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis.Front Oncol. 2022 Jun 23;12:907584. doi: 10.3389/fonc.2022.907584. eCollection 2022. Front Oncol. 2022. PMID: 35814419 Free PMC article. Review.
-
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.JACC CardioOncol. 2021 Oct 19;3(4):467-487. doi: 10.1016/j.jaccao.2021.09.003. eCollection 2021 Oct. JACC CardioOncol. 2021. PMID: 34729520 Free PMC article. Review.
-
Electrocardiographic parameters and prognosis of renal light chain amyloidosis.Clin Cardiol. 2020 Oct;43(10):1160-1166. doi: 10.1002/clc.23426. Epub 2020 Jul 28. Clin Cardiol. 2020. PMID: 33460229 Free PMC article.
-
Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.Sci Rep. 2025 Jul 11;15(1):25149. doi: 10.1038/s41598-025-09498-7. Sci Rep. 2025. PMID: 40646057 Free PMC article.
References
-
- Kyle RA, Bayrd ED. “Primary” systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Arch Intern Med 1961;107344–353. - PubMed
-
- Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic Proceedings 1983;58(10):665–683. - PubMed
-
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology 1995;32(1):45–59. - PubMed
-
- Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. [see comment]. Blood 1992;79(7):1817–1822. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous